Orientation Workshop on code on Good Manufacturing Practice, 2072 (Second Amendment-2082) for Ayurveda Domestic Industry

Kathmandu, August 22, 2025 — The Department of Drug Administration (DDA) organized an Orientation Workshop on code on Good Manufacturing Practice (GMP) Second Amendment for Ayurveda Domestic Manufacturers at the DDA Meeting Hall. The program was chaired by Mr. Narayan Prasad Dhakal, Director General of DDA.

The workshop aimed to familiarize domestic Ayurveda manufacturers with the updated legal provisions and technical requirements introduced under the GMP Second Amendment, ensuring safety, efficacy, and quality in Ayurvedic and traditional medicine production.

Pharmacy Officer Mr. Rajesh Shrestha presented an outline on the following key areas:

• Legal Provision of Code on GMP
• Supreme Court Decision 079-WO-0798
• Components of GMP Code
• Provisions Related to Ayurvedic Formulations

Following this, Ayurveda Physician Dr. Rupendra Puri delivered an in-depth session on specialized manufacturing standards. His presentation focused on:

• Additional Provisions for the Preparation of Rasa (Herbo-mineral formulations), Bhasma (Calcined preparations), Satva (Extracts), Dhatu (Metals), and Kupipakwa (Sealed-jar processed) Ayurvedic Medicines under Subsection 12 of Chapter 13
• General Principles Related to These Provisions

After the presentations, a question-and-answer session was held, where attendees and technical representatives from manufacturing companies raised queries. These were addressed directly by DDA officials, providing further clarity on regulatory provisions and practical implementation challenges.

The program brought together regulatory officials, Ayurveda experts, and representatives of domestic manufacturing companies. Participants engaged in constructive discussions on compliance issues and the future direction of the sector.

Speaking at the conclusion, DG Dhakal emphasized that the orientation was an important step toward strengthening Nepal’s Ayurveda industry through better regulation and standardization. He highlighted the DDA’s commitment to supporting manufacturers in adopting updated GMP practices to ensure safe and quality healthcare for the public. He also directed domestic Ayurveda manufacturers to submit their work plan within 15 days for the effective implementation of the Code on Good Manufacturing of Ayurveda Medicines.